Worth reading
49Recurring
Scored from 4 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Definitive
How definitive the wording is.Agreements reached under this partnership
Discontinuation206APRISM BioLab Co.,LTD
Alliance partnerMerck Healthcare KGaA
Details of the alliance
- 1
Provision of the PepMetics® library for screening against Merck's drug discovery targets
- 2
Advance research and development based on hit compounds
- 3
Receive consideration from Merck for the use of the compounds
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
Impact on Business Performance
This matter will have no impact on the Company's performance.
Contract Date12 October 2020Contract PeriodEnded upon expiration of the contract term
| Item | Details |
|---|---|
| Name of alliance partner | Merck Healthcare KGaA |
| Type of alliance | Discontinuation |
| Details of the alliance | Provision of the PepMetics® library for screening against Merck's drug discovery targets, Advance research and development based on hit compounds, Receive consideration from Merck for the use of the compounds |
| Contract Period | Ended upon expiration of the contract term |
| Contract Date | 12 October 2020 |
| Impact on Business Performance | This matter will have no impact on the Company's performance. |
Items this document does not state (17)
Alliance partner's business activitiesAlliance partner's locationAlliance partner's capitalAlliance partner's net salesAlliance partner's operating incomeNumber of shares acquiredAcquisition priceShareholding ratioOverview of the joint ventureOwnership ratioDispatch of directors and officersNumerical targets under the allianceShareholding PolicyDate of board resolutionAlliance start dateShare Acquisition Date and Payment DateChange in major shareholders
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The contract term expired, and following discussions between the two companies regarding future arrangements, they agreed to terminate the agreement effective 13 November 2026.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.